临时机械循环支持对持久心室辅助装置结局的纵向影响:IMACS登记倾向匹配分析
该研究基于2013-2017年IMACS登记中13,813例INTERMACS 1-3级接受持久心室辅助装置(dVAD)的成人患者,分析术前临时循环支持(TCS)类型对纵向结局的影响。结果显示,术前ECMO患者较IABP、其他TCS及非TCS患者纵向生存率更低,且双心室支持需求和ICU住院时间更长;倾向匹配分析中ECMO与早期生存风险升高相关。
要点
- 术前ECMO与dVAD后更低纵向生存率及更高双心室支持需求相关。
- ECMO组ICU住院时间最长,IABP次之,其他TCS最短。
- 倾向匹配分析中ECMO较其他TCS和IABP早期生存风险更高。
核心结论
- 在伴有心源性休克的晚期心衰患者中,dVAD术前使用ECMO较其他临时循环支持策略与更低的纵向生存率和更高的双心室支持使用率相关。
研究设计与样本
- 回顾性登记分析纳入2013-2017年IMACS登记中13,813例INTERMACS 1-3级接受连续流左心室辅助装置或双心室辅助装置的成人患者。
- 按术前临时循环支持类型分为ECMO、IABP和其他TCS亚组,并比较生存及倾向评分匹配分析。
主要发现
- 术前TCS使用于5,632例(41%),其中ECMO 1,138例(20%)、IABP 3,901例(69%)、其他TCS 595例(11%)。
- dVAD后需双心室支持比例:ECMO 22%、IABP 5%、其他TCS 7%(p < 0.001)。
- dVAD后ICU住院时间:ECMO 24天、IABP 14天、其他TCS 12天(p < 0.001)。
- INTERMACS 1-3级患者纵向生存率:ECMO 1个月82%、48个月44%;IABP 93%、51%;其他TCS 92%、52%;非TCS 95%、55%(p < 0.0001)。
- 倾向匹配分析中,术前ECMO的INTERMACS 1级患者较其他TCS早期生存风险比1.80(p < 0.01),较IABP风险比1.65(p < 0.01)。
临床怎么用
- 对于需dVAD的晚期心衰合并心源性休克患者,选择术前临时循环支持策略时应考虑ECMO与更差纵向生存及更高双心室支持需求的关联。
局限性
- 原文未报告局限性内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with advanced heart failure and cardiogenic shock (CS) often require temporary circulatory support (TCS) as a bridge to durable ventricular assist devices (dVADs). We aim to characterize longitudinal outcomes of patients with and without CS. METHODS: Between 2013 and 2017, 13,813 adult patients classified as Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) Profiles 1 to 3 with continuous flow left ventricular assist devices or biventricular assist devices were registered into the International Society for Heart and Lung Transplantation Registry for Mechanically Assisted Circulatory Support. Patients were sub-grouped according to support type (extracorporeal membrane oxygenation [ECMO], intra-aortic balloon pump [IABP], and other TCS). Other TCS included all other surgical and percutaneous TCS devices. Estimated survival was compared based on need for pre-operative TCS and by profile. RESULTS: Pre-operative TCS was used in 5,632 (41%) cases. Of these, ECMO was used in 1,138 (20%) cases, IABP in 3,901 (69%) cases, and other TCS in 595 (11%) cases. Patients requiring ECMO had greater needs for biventricular support after dVAD (22% ECMO, 5% IABP, and 7% other TCS; p < 0.001) with longer post-implant intensive care stays (ECMO 24 days, IABP 14 days, and other TCS 12 days; p < 0.001). INTERMACS Profile 1 to 3 patients with pre-implant ECMO had the lowest longitudinal survival (82% at 1 month and 44% at 48 months) compared with IABP (93% at 1 month and 51% at 48 months), other TCS (92% at 1 month and 52% at 48 months), and non-TCS (95% at 1 months and 55 % at 48 months) (p < 0.0001). Propensity score matching analysis of the pre-implant ECMO INTERMACS Profile 1 group when compared with alternative pre-implant TCS strategies had an associated higher hazard impacting early phase survival vs other TCS (hazard ratio, 1.80; p < 0.01) and IABP (hazard ratio, 1.65; p < 0.01). CONCLUSIONS: In advanced heart failure with patients with CS, the use of ECMO before dVAD was associated with lower longitudinal survival and increased utilization of biventricular support compared with alternative TCS strategies. Research focused on longitudinal profiling in CS and pre-implant TCS is warranted to further understand these differences.
引用
- Hernandez-Montfort JA, Xie R, Ton VK, et al. Longitudinal impact of temporary mechanical circulatory support on durable ventricular assist device outcomes: An IMACS registry propensity matched analysis. J Heart Lung Transplant. 2019. PMID: 31866174. doi:10.1016/j.healun.2019.11.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。